Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) from a strong sell rating to a sell rating in a research report released on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings initiated coverage on Lakewood-Amedex Biotherapeutics in a report on Monday, July 20th. They issued a “sell (e-)” rating for the company. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Lakewood-Amedex Biotherapeutics Trading Up 16.0%

Shares of Lakewood-Amedex Biotherapeutics stock opened at $2.18 on Friday. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $1.66 and a fifty-two week high of $98.20. The business’s fifty day simple moving average is $2.34. The stock has a market cap of $5.17 million and a price-to-earnings ratio of -0.46.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last announced its quarterly earnings data on Friday, August 14th. The company reported ($2.75) EPS for the quarter. On average, analysts forecast that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current fiscal year.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.